This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Madrigal (MDGL) delivered earnings and revenue surprises of 5.96% and 286.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 38.46% and 53.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
by Zacks Equity Research
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
by Zacks Equity Research
Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of -65% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?
by Zacks Equity Research
Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.
Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMLX vs. NBIX: Which Stock Is the Better Value Option?
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
by Zacks Equity Research
Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Amylyx (AMLX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amylyx (AMLX) stock based on the movements in the options market lately.
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 3,000% and 16.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Carnival, Amylyx Pharmaceuticals and Alkami Technology
by Zacks Equity Research
Carnival, Amylyx Pharmaceuticals and Alkami Technology have been highlighted in this Screen of The Week article.
3 Stocks Worth a Buy for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Some of the notable companies to have witnessed solid earnings acceleration as of now are Carnival (CCL), Amylyx Pharmaceuticals (AMLX) and Alkami Technology (ALKT).
Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate
by Zacks Equity Research
Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 107.41% and 24.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study
by Zacks Equity Research
Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
by Zacks Equity Research
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.